United Therapeutics
UTHR
386 hedge funds and large institutions have $10.7B invested in United Therapeutics in 2015 Q4 according to their latest regulatory filings, with 67 funds opening new positions, 156 increasing their positions, 121 reducing their positions, and 52 closing their positions.
69% more call options, than puts
Call options by funds: $67M | Put options by funds: $39.6M
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
29% more repeat investments, than reductions
Existing positions increased: 156 | Existing positions reduced: 121
29% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 52
24% more capital invested
Capital invested by funds: $8.63B → $10.7B (+$2.04B)
4% more funds holding
Funds holding: 372 → 386 (+14)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSV Asset Management
Chicago,
Illinois
|
+$87.4M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$70.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$64.3M |
| 4 |
Goldman Sachs
New York
|
+$56.8M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
+$51.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
-$259M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$84.8M |
| 3 |
First Eagle Investment Management
New York
|
-$72M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
-$71.2M |
| 5 |
Renaissance Technologies
New York
|
-$45.8M |
UTHR Hedge Fund Activity: Q4 2015 in Review
386 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q4 2015, worth a combined $10.7B — up 24% from $8.63B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new UTHR positions and 52 closed out — a net gain of 15 holders — while 156 added to existing stakes and 121 trimmed.
The largest buyer was LSV Asset Management, adding an estimated $87.4M. The largest seller was Iridian Asset Management, exiting entirely with an estimated $259M sold.
- 386 institutional investors held United Therapeutics (UTHR) as of Q4 2015, up from 372 in Q3 2015.
- Funds reported $10.7B of United Therapeutics stock for Q4 2015, up 24% quarter-over-quarter.
- 67 funds opened new United Therapeutics positions in Q4 2015 and 52 closed out, a net change of +15 holders.
- The largest United Therapeutics buyer in Q4 2015 was LSV Asset Management, an estimated $87.4M added.
- The largest United Therapeutics seller in Q4 2015 was Iridian Asset Management, an estimated $259M sold.
Based on aggregated 13F filings for Q4 2015.